RS65040B1 - Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)uree kao kcnq potencijatori - Google Patents
Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)uree kao kcnq potencijatoriInfo
- Publication number
- RS65040B1 RS65040B1 RS20240009A RSP20240009A RS65040B1 RS 65040 B1 RS65040 B1 RS 65040B1 RS 20240009 A RS20240009 A RS 20240009A RS P20240009 A RSP20240009 A RS P20240009A RS 65040 B1 RS65040 B1 RS 65040B1
- Authority
- RS
- Serbia
- Prior art keywords
- kcnq
- potentiators
- trifluoroethoxy
- pyridin
- methyl
- Prior art date
Links
- VDRSSRINXUQZRZ-UHFFFAOYSA-N [2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methylurea Chemical class FC(COC1=NC=CC(=C1)CNC(=O)N)(F)F VDRSSRINXUQZRZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962801716P | 2019-02-06 | 2019-02-06 | |
| US201962811038P | 2019-02-27 | 2019-02-27 | |
| PCT/US2020/016499 WO2020163268A1 (en) | 2019-02-06 | 2020-02-04 | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators |
| EP20709409.5A EP3921030B1 (en) | 2019-02-06 | 2020-02-04 | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65040B1 true RS65040B1 (sr) | 2024-02-29 |
Family
ID=69743945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240009A RS65040B1 (sr) | 2019-02-06 | 2020-02-04 | Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)uree kao kcnq potencijatori |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11208383B2 (sr) |
| EP (1) | EP3921030B1 (sr) |
| JP (1) | JP7451543B2 (sr) |
| KR (1) | KR20210126040A (sr) |
| CN (1) | CN113692304A (sr) |
| AU (1) | AU2020218180A1 (sr) |
| BR (1) | BR112021015544A2 (sr) |
| CA (1) | CA3128975A1 (sr) |
| DK (1) | DK3921030T3 (sr) |
| FI (1) | FI3921030T3 (sr) |
| HR (1) | HRP20240012T1 (sr) |
| IL (1) | IL285113A (sr) |
| LT (1) | LT3921030T (sr) |
| MX (1) | MX2021009396A (sr) |
| PT (1) | PT3921030T (sr) |
| RS (1) | RS65040B1 (sr) |
| SG (1) | SG11202108599SA (sr) |
| SI (1) | SI3921030T1 (sr) |
| WO (1) | WO2020163268A1 (sr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3921030T (lt) * | 2019-02-06 | 2024-01-25 | Eli Lilly And Company | 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai |
| US20230303486A1 (en) | 2020-06-25 | 2023-09-28 | Idorsia Pharmaceuticals Ltd | Cyclobutyl-urea derivatives |
| WO2023054626A1 (ja) * | 2021-09-30 | 2023-04-06 | 住友ファーマ株式会社 | シクロプロパンアミド誘導体 |
| WO2023091554A1 (en) | 2021-11-19 | 2023-05-25 | Icagen, Llc | Novel heteroaryl-urea compounds as kv7.2 inhibitors |
| WO2023091461A1 (en) | 2021-11-19 | 2023-05-25 | Icagen, Llc | Pyridine compounds as kv7.2 enhancers |
| WO2023121992A1 (en) | 2021-12-22 | 2023-06-29 | Icagen, Llc | Cyclopropyl compounds |
| WO2023158584A1 (en) | 2022-02-15 | 2023-08-24 | Icagen, Llc | New bicyclopentane derivatives |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005233642A1 (en) | 2004-04-13 | 2005-10-27 | Astellas Pharma Inc. | Polycyclic pyridines as potassium ion channel modulators |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| CN103709097A (zh) | 2012-09-28 | 2014-04-09 | 中国科学院上海药物研究所 | 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用 |
| CN105228620B (zh) | 2013-03-15 | 2020-09-04 | 德西费拉制药有限责任公司 | 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物 |
| CN106255679B (zh) | 2014-02-27 | 2019-09-06 | 默克专利有限公司 | 用作nav通道抑制剂的杂环化合物及其用途 |
| CN107108485B (zh) | 2014-10-24 | 2020-06-12 | 小野药品工业株式会社 | Kcnq2～5通道活化剂 |
| ES2866324T3 (es) | 2016-04-22 | 2021-10-19 | Ono Pharmaceutical Co | Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria |
| LT3921030T (lt) * | 2019-02-06 | 2024-01-25 | Eli Lilly And Company | 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai |
-
2020
- 2020-02-04 LT LTEPPCT/US2020/016499T patent/LT3921030T/lt unknown
- 2020-02-04 DK DK20709409.5T patent/DK3921030T3/da active
- 2020-02-04 MX MX2021009396A patent/MX2021009396A/es unknown
- 2020-02-04 BR BR112021015544-9A patent/BR112021015544A2/pt unknown
- 2020-02-04 JP JP2021546360A patent/JP7451543B2/ja active Active
- 2020-02-04 CA CA3128975A patent/CA3128975A1/en active Pending
- 2020-02-04 SI SI202030316T patent/SI3921030T1/sl unknown
- 2020-02-04 SG SG11202108599SA patent/SG11202108599SA/en unknown
- 2020-02-04 FI FIEP20709409.5T patent/FI3921030T3/fi active
- 2020-02-04 HR HRP20240012TT patent/HRP20240012T1/hr unknown
- 2020-02-04 PT PT207094095T patent/PT3921030T/pt unknown
- 2020-02-04 US US16/781,148 patent/US11208383B2/en active Active
- 2020-02-04 WO PCT/US2020/016499 patent/WO2020163268A1/en active Application Filing
- 2020-02-04 RS RS20240009A patent/RS65040B1/sr unknown
- 2020-02-04 CN CN202080012797.0A patent/CN113692304A/zh active Pending
- 2020-02-04 KR KR1020217028040A patent/KR20210126040A/ko unknown
- 2020-02-04 EP EP20709409.5A patent/EP3921030B1/en active Active
- 2020-02-04 AU AU2020218180A patent/AU2020218180A1/en active Pending
-
2021
- 2021-07-25 IL IL285113A patent/IL285113A/en unknown
- 2021-11-19 US US17/531,000 patent/US11840516B2/en active Active
-
2023
- 2023-11-09 US US18/388,299 patent/US20240076269A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200247752A1 (en) | 2020-08-06 |
| FI3921030T3 (fi) | 2024-01-08 |
| IL285113A (en) | 2021-09-30 |
| CA3128975A1 (en) | 2020-08-13 |
| DK3921030T3 (da) | 2024-01-02 |
| WO2020163268A1 (en) | 2020-08-13 |
| US20240076269A1 (en) | 2024-03-07 |
| SG11202108599SA (en) | 2021-09-29 |
| KR20210126040A (ko) | 2021-10-19 |
| US11208383B2 (en) | 2021-12-28 |
| EP3921030B1 (en) | 2023-10-11 |
| AU2020218180A1 (en) | 2021-08-19 |
| US20220073464A1 (en) | 2022-03-10 |
| US11840516B2 (en) | 2023-12-12 |
| MX2021009396A (es) | 2021-09-10 |
| CN113692304A (zh) | 2021-11-23 |
| LT3921030T (lt) | 2024-01-25 |
| SI3921030T1 (sl) | 2024-03-29 |
| JP7451543B2 (ja) | 2024-03-18 |
| EP3921030A1 (en) | 2021-12-15 |
| PT3921030T (pt) | 2024-01-12 |
| BR112021015544A2 (pt) | 2021-10-26 |
| JP2022519744A (ja) | 2022-03-24 |
| HRP20240012T1 (hr) | 2024-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285113A (en) | History of 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea as kcnq enhancers | |
| IL288104A (en) | Heterocyclic compounds, preparation methods and their use | |
| IL280701A (en) | History of 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(3,2-dichlorophenyl)-2-methylpyrimidin-4(H3)-one and compounds related as PTPN11 (SHP2) inhibitors for cancer treatment | |
| ZA202006944B (en) | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | |
| EP4077311A4 (en) | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION PROCESSES AND THEIR USES | |
| ATE516272T1 (de) | 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one | |
| EP1954683A4 (en) | 2- (PHENYL OR HETEROCYCLIC) -1H-PHENANTRHO (9,10-D) IMIDAZOLES AS INHIBITORS OF MPGES-1 | |
| IL252844B (en) | Process for preparing 4-(3-(-6-cyano-5-(trifluoromethyl)pyridin-3-yl)-4-oxo-2-thio-3,1-diazaspiro[5,4]-octan-1-yl) -2- fluoro-n-methylbenzamide | |
| IL268690A (en) | (4)- 1-(1-(S-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(1-methyl-H1-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridine-2 (H1)-Onat salts and their crystalline structures and pharmaceutical preparations containing them | |
| EP3927696C0 (en) | CRYSTALLINE FORM OF 1-(1-OXO-1,2-DIHYDROISOCINOLINE-5-YL)-5-(TRIFLUORMETHYL)-(2-(TRIFLUORMETHYL)PYRIDINE-4-YL)-1H-PYRAZOLE-4-CARBOXAMIDE MONOHYDRATE | |
| IL289951A (en) | A urea compound as an lpa1 receptor antagonist | |
| EP4194449A4 (en) | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | |
| HK1243416A1 (zh) | 1-((2r，4r)-2-(1h-苯並[d]咪唑-2-基)-1-甲基呱啶-4-基)-3-(4-氰基苯基)脲馬來酸鹽的晶形 | |
| MX2018006329A (es) | Agente terapeutico para cancer de mama. | |
| DK3720438T3 (da) | Svampedræbende midler, der er afledt af heterocyklus-substitueret pyridin | |
| EP3833343A4 (en) | HETEROCYCLIC FLAVON DERIVATIVES, COMPOSITIONS AND RELATED METHODS THEREOF | |
| SI3559010T1 (sl) | Postopek za pripravo 5-((4-(2-(5-(1-hidroksietil)-2-piridinil)etoksi) fenil)metil)-2,4-tiazolidindiona in soli le-tega | |
| EP3541796A4 (en) | 4 - ((6- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H | |
| EP3303320A4 (en) | Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same | |
| MX2020002622A (es) | Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida. | |
| MA49068A (fr) | Composé n-(4-pyridyl) nicotinamide ou sel de celui-ci | |
| SG11201809760TA (en) | Novel 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof | |
| SI3292133T1 (sl) | Postopek priprave 2-(4-(2-(((2-(4-klorofenil)-1,3-tiazol-4-il)metil)sulfanil)-3,5-dician- 6-(pirolidin-1-il)piridin-4-il)fenoksi)etil-L-alanil-L-alaninat hidroklorida | |
| DK3947711T3 (da) | Urinstofbiosensorer, der er stabiliseret ved rumtemperatur | |
| EP3541797A4 (en) | 4 - ((6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H |